November 5, 2020
Justin Lathia to present Division of Biology Seminar
Submitted by Division of Biology
Justin Lathia, associate professor in the Department of Cellular and Molecular Medicine at the Lerner Research Institute, a part of the Cleveland Clinic, will present "What Is Good for Adam May Not be Good for Eve: How Underlying Sex Difference in Glioblastoma May Provide New Insights" as part of the Division of Biology Seminar Series at 3:30 p.m. CST Monday, Nov. 9, via Zoom.
Glioblastoma, or GBM, is the most common primary malignant brain tumor and despite aggressive multi-modal therapies, including surgical resection and concomitant radiation and chemotherapy, is associated with a poor prognosis. The overall survival has not increased dramatically over the last 30 years and identifying targetable cellular and molecular mechanisms in GBM remains a priority. GBM has a sexual dimorphism in incidence and outcome, with males experiencing a higher incidence of GBM and a poorer prognosis. These sex differences are an emerging area of interest and studies have revealed sex-specific genetic aberrations and cellular programs that manifest in differences in imaging characteristics and therapeutic response. The seminar will include discussion of additional cellular and molecular insights using pre-clinical models in terms of immune response that underlie GBM progression. While GBM is being used as a paradigm for these assessments, these sex differences have implications for other advanced cancers and neurological disorders.
If you would like to visit with Lathia, please contact Nirupama Kotian at email@example.com.